Virogin Biotech Ltd.

Thought leaders at the Cancer Progress conference in New York City March 4-5 delved into some of the biggest obstacles standing in the way of industry’s ambition to harness big data – the complex and

Roche ’s position in the breast cancer market got even better Feb. 22 with FDA’s approval of its antibody-drug conjugate Kadcyla (ado-trastuzumab emtansine) as a second-line option after treatment

Roche ’s position in the breast cancer market got even better Feb. 22 with FDA’s approval of its antibody-drug conjugate Kadcyla (ado-trastuzumab emtansine) as a second-line option after treatment

Roche reports it has had no pushback on pricing for Perjeta in the U.S., but the Swiss pharma giant will have to “get creative” with its approach to marketing the breast cancer drug in Europe, the